<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58736">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01948934</url>
  </required_header>
  <id_info>
    <org_study_id>MA/GH</org_study_id>
    <secondary_id>2011-004395-11</secondary_id>
    <nct_id>NCT01948934</nct_id>
  </id_info>
  <brief_title>Clinic Trial in Phase 1 Using Amniotic Membrane for the Skin Replacement in Big Wounds</brief_title>
  <official_title>Clinic Trial in Phase 1 Using Amniotic Membrane for the Skin Replacement in Big Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of use of a new therapeutic strategy
      for the treatment of patients with large wounds
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amniotic membrane (AM) is a useful tissue as a biological dressing with numerous advantages
      it has a very similar structure to the skin and his biological and immunological properties.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>serious adverse events</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>inflammatory changes</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>wound evaluation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>inflammatory condition of the wound,surface,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunological evaluation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>anti Human Leukocyte Antigen 1 (HLA1),Short Tandem Repeat (STRS) detection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>histological evaluation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Transforming growth factor beta 1 or Transforming growth factor beta (TGFB),wound biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microbiological evaluation</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>microbiological culture</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Wound</condition>
  <arm_group>
    <arm_group_label>amniotic membrane in big wounds</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Amniotic membrane in big wounds</intervention_name>
    <description>The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue</description>
    <arm_group_label>amniotic membrane in big wounds</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute wounds in granulation phase with a minimum surface of 100cm2

          -  â‰¥ 18 years

          -  signing informed consent form

          -  guarantee adherence to protocol

        Exclusion Criteria:

          -  chronic arterial insufficiency

          -  pregnant patients, lactating women or fertile adults that they don`t use an effective
             contraceptive method

          -  involved in other assay

          -  previous disease; kidney, heart, hepatic, systemic or immune

          -  inability to understand informed consent form
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregorio Castellanos Escrig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinico Universitario Virgen de la Arrixca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gregorio Castellanos Escrig, MD</last_name>
    <phone>968369500</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Gregorio Castellanos Escrig MD</name>
      <address>
        <city>Murcia</city>
        <state>El Palmar</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregorio Castellanos Escrig, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 17, 2014</lastchanged_date>
  <firstreceived_date>September 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin</keyword>
  <keyword>Injury</keyword>
  <keyword>Membrane amniotic</keyword>
  <keyword>Wound</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
